Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
Authors' conclusion
Real-world evidence suggests multimorbidity is common among tirzepatide initiators. While tirzepatide dose escalation was slower than in clinical trials, individuals achieved weight reduction at 6 months, consistent with clinical trials.
Study context
- Population
- Adults ≥18 years without T2D initiating tirzepatide, US (index period 13 May 2022–30 September 2023)overall cohort
- Participants
- 20,998 adults
- Outcome
- Tirzepatide utilization and effectiveness (change in weight and BMI)
- Follow-up
- 6 months post-index
Methodological detailsdescriptive analyses, Optum Market Clarity database
- Descriptive analyses
- Optum Market Clarity database
Main finding
As reported in the abstract
Mean weight reduction (effectiveness cohort)
Mean weight reduction
11.9%
Weight reduction ≥5%
85.8%
Weight reduction ≥10%
61.5%
Observational data: associations, not effects.
Further findings
Utilization cohort · 6 months post-index
- Persistence
- 55.4%
- Switched to different anti-obesity medication (AOM)/GLP-1 RA or restarted tirzepatide after discontinuation
- 30.8%
- On <10 mg tirzepatide by sixth prescription fill
- 74.2%
Baseline multimorbidity (overall cohort) · index
- ≥1 obesity-related complication
- 66.0%
- ≥2 obesity-related complications
- 44.4%
Original publication
Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database. Diabetes Obes Metab. Published 25 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →